LILRB1 and non-Hodgkin lymphoma: Therefore, we utilized models resistant to previous lines of immunotherapy [25] in B-NHL cell lines that were LILRB1-positive (surprisingly, LILRB1 was expressed only in 2 out of 8 analyzed B-ALL cell lines and 4 out of 6 B-NHL cell lines) (Supplementary Fig. 4A, B).